Madrigal pharmaceuticals presents phase 3 maestro-nash data during the opening general session of the easl congress™

Conshohocken, pa., june 22, 2023 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today presents resmetirom phase 3 maestro-nash data at the opening general session of the european association for the study of the liver congress (easl 2023).
MDGL Ratings Summary
MDGL Quant Ranking